Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorFudan University
About this trial
The purpose of this study is to evaluate the efficacy of cisplatin based regimen to patients with advanced pancreatic cancer and homologous recombination deficiency.
Eligibility criteria
Qualifiers
Ability to understand and the willingness to sign a written informed consent document.
Age ≥ 18 years and ≤ 80 years.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Histologically or cytologically confirmed advanced pancreas adenocarcinoma.
Disqualifiers
Pregnant or nursing women.
Primary pancreatic cancer.
Patients who have received platinum or PARPi treatment.
The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas.
Trial design
Treatments tested in this trial
- Cisplatin
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov